Showing results (81-90 of 90) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of the Neurological Sciences|May 1, 1986
Quantitation of myelination and demyelination by the measurement of myelin basic protein by ELISAR N Nishimura, J Wang, J E Merrill, et al.Journal of Autism and Developmental Disorders|March 1, 1992
Hyperserotoninemia and antiserotonin antibodies in autism and other disordersA Yuwiler, J C Shih, C H Chen, et al.Lancet (London, England)|October 26, 1991
Overview of azathioprine treatment in multiple sclerosisP L Yudkin, G W Ellison, A Ghezzi, et al.Archives of Neurology|January 1, 1990
Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesisR W Baumhefner, W W Tourtellotte, K Syndulko, et al.American Journal of Veterinary Research|June 22, 1999
Scintigraphic, sonographic, and histologic evaluation of renal autotransplantation in catsS M Newell, G W Ellison, J P Graham, et al.Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.Brain : a Journal of Neurology|June 4, 1999
Development of a multiple sclerosis functional composite as a clinical trial outcome measureG R Cutter, M L Baier, R A Rudick, et al.Pageof 9